Biotech Values

[DewDiligence]

Rocky et al: Your IMS numbers in #msg-53904946 are entirely consistent with the numbers I posted in #msg-53930739. Prior to the generic launch, branded Lovenox had weekly total scripts (TRx) in the range of 54-56K. (The week ending Jul 9 was a holiday week and was slightly lower as one would expect.)

Your Jul 30 data covers the first week following the generic launch and shows that branded scripts dropped by about 1,500 relative to the previous week while generic scripts rose by 1,700—i.e., the initial erosion of branded Lovenox from penetration by the generic.

My data in #msg-53930739 from one week later (the week ending Aug 6) shows that the trickle of erosion during the first post-launch week turned into a river during the second post-launch week as branded scripts fell by 9,000 relative to the previous week and generic scripts presumably increased by a similar number.